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INTRODUCTION:  Opportunistic  pathogens  can  cause  severe  damage  leading  to irreversible  complications
in  immune-compromised  patients.  Here  we  describe  a patient  who  sustained  Blastocystis  hominis  infec-
tion resulting  in  severe  sepsis  while  on  extracorporeal  membrane  oxygenation  (ECMO)  support,  and  the
course  of treatment  taken  to treat him.
PRESENTATION  OF  CASE:  Our  case,  a  34-year-old  Filipino  man,  was hospitalized  for  valvular  disease  and
received valve  replacements.  ECMO  and an intra-aortic  balloon  pump  (IABP)  were  implemented  when  the
patient  developed  progressive  heart  failure  after  cardiac  surgery.  Unfortunately,  the  patient  suffered  from
sepsis  with  persistent  fever  and  diarrhea,  and  subsequent  examinations  indicated  the  patient  was  infected
by  B.  hominis.  After  adequate  administration  of the  antibiotic  metronidazole,  the  patient’s  symptoms
subsided  and  he  was  discharged.
DISCUSSION:  Blastocystis  hominis  is a unicellular  protozoa  commonly  found  in the  intestinal  tract,  and
the  prevalence  of B. hominis  is  1.5–10%  in  developed  countries  and  30–50%  in  developing  countries.  The
patient  needed  the  support  of  ECMO  and  IABP,  was  immunocompromised  to  a certain  extent;  B.  hominis
can  be a harmful  opportunistic  pathogen  for them  and  lead  to severe  irreversible  complications  such  as
death.
CONCLUSION:  This  is the  ﬁrst  published  article  showing  that  the  opportunistic  pathogen,  B.  homi-
nis,  can cause  severe  infection  in  patients  on  ECMO  support,  a result  that  should  be  kept  in  mind
when  patients  come  from  a place  with  a  high  prevalence  of  B. hominis.  The  prophylactic  medication
should  be administered  routinely  when  patients  live  in  the  region  and  extracorporeal  life-support  is
used.
© 2014  The  Authors.  Published  by Elsevier  Ltd.  on behalf  of  Surgical  Associates  Ltd.  This  is  an  open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Introduction
Blastocystis hominis, a unicellular protozoa commonly found in
he intestinal tract, can lead to gastrointestinal symptoms such
s diarrhea, nausea, abdominal pain, vomiting, and bloating.1–3
he prevalence of B. hominis is 1.5–10% in developed countries,
here it can sometimes act as an opportunistic pathogen, result-
ng in deterioration of health in immune-compromised patients.4
n Taiwan, use of extracorporeal membrane oxygenation (ECMO), a
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http://creativecommons.org/licenses/by-nc-nd/3.0/).powerful life-support system, is currently a popular means of
keeping patients in critical condition alive. Any type of infec-
tion in patients on ECMO support is bound to become a serious
complication.5 Meanwhile, patients on ECMO support are immune-
compromised to a certain extent; therefore, they have an increased
probability of being infected by B. hominis. ECMO patients suffer
from hemodynamic instability and weak constitutions, and all fac-
tors that might lead to deterioration, including infections, should be
carefully considered and prevented. The purpose of this paper is to
describe the clinical presentation of this opportunistic pathogen,
Blastocystis hominis, infecting a patient on ECMO support in the
intensive care unit, a scenario never before reported in the litera-
ture, and to try to caution clinicians to be aware of the possibility
of B. hominis infection in ECMO patients in order to prevent an
unnecessarily bad outcome.
ssociates Ltd. This is an open access article under the CC BY-NC-ND license
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. Case report
Our patient was a 34-year-old Filipino man  who had been work-
ng in Taiwan for 9 years. He was hospitalized for intermittent
dema of the legs, easily induced fatigue, and progressive cough
xperienced over the 9 months prior to admission. At the time of
dmission, chest radiography revealed bilateral lung edema with
ardiomegaly. Cardiac sonography revealed aortic valve stenosis
nd mitral valve regurgitation; therefore, double valve replace-
ent including the aortic valve and the mitral valve were suggested
nd performed. After the surgical intervention, a transesophageal
chocardiogram revealed no residual valvular event; however,
lobal hypokinesia was still observed during the examination.
nitially, the global hypokinesia was considered as a transient
nﬂuence of the cardiac manipulation. When hemodynamic sta-
us gradually worsened and cardiogenic shock eventually occurred,
CMO and an IABP were employed due to the emergency of the
ituation resulting from hemodynamic instability. Since electrocar-
iography showed a diffuse Q wave in the anterolateral lead after
ardiogenic shock, cardiac catheterization was performed under
upport with ECMO and IABP, revealing left main coronary artery
tenosis. Percutaneous occlusive balloon angioplasty stenting was
erformed for that, and hemodynamic instability improved gradu-
lly thereafter.
Unfortunately, persistent fever and diarrhea subsequently
eveloped with leukocytosis. A blood test revealed a leuko-
yte count of 19.58 K/L  with a segment type of 81.4 percent;
emoglobin level of 11.1 g/dL; and platelet count of 42 K/L.
he blood levels of urea nitrogen, creatinine, aspartate transami-
ase, alanine transaminase, and total bilirubin were respectively
6.5 mg/dL, 0.9 mg/dL, 191 U/L, 103 U/L, and 6.99 mg/dL. Parenteral
efpirome 2000 mg  every twelve hours and parenteral teicoplanin
00 mg  daily were administered empirically. The infectious dis-
ases physician suggested that the patient should be weaned off
CMO and IABP in order to allow clear identiﬁcation of the infec-
ion. A septic work-up, including atypical infectious pathogens, was
ompleted. Both blood culture and sputum culture obtained neg-
tive results. An indirect hemagglutination test for amebiasis was
lso negative. The titers of coxsackie B virus antibodies including
ubtypes B1–B6 were 1:2 and not signiﬁcant. Only the stool culture
howed positive for B. hominis without development of Clostrid-
um difﬁcile.  On the basis of these clinical ﬁndings and discussion
ith the infectious diseases physician, we substituted cefpirome
nd teicoplanin with 500 mg  of oral metronidazole three times a
ay. After 13 days of metronidazole treatment no further fever or
bdominal discomfort was noted and the patient was  discharged
ithout complications.
. Discussion
Blastocystis hominis is a unicellular protozoa commonly found
n the intestinal tract. It is classiﬁed taxonomically within the het-
rogeneous group of stramenopiles.6,7 B. hominis has 6 life-cycle
tages, namely, the amoeboid, avacuolar, vacuolar, multivacuolar,
ranular, and cystic stages.1 In each stage, the presence of the
entral vacuole, the cell wall, the number of nuclei, and the size
ary. Nine of the 10 subtypes of B. hominis can infect humans,
he most common being subtype 3.8 The cyst form of B. homi-
is is transmitted via the fecal-oral route.9 The association of B.
ominis with abdominal discomfort has not yet been elucidated;
owever, we have been able to isolate B. hominis from individuals
ith gastrointestinal symptoms such as diarrhea, nausea, abdomi-
al pain, vomiting, and bloating.1–3 It is even known to embed itself
n the intestinal mucosa, contributing to large ulcers.10 The preva-
ence of B. hominis is 1.5–10% in developed countries and 30–50%PEN  ACCESS
rgery Case Reports 5 (2014) 637–639
in developing countries.2 Various diagnostic tests are available to
determine the infection of B. hominis, such as examination of direct
smears, xenic in vitro culture, formol ethyl acetate concentration,
and polymerase chain reaction.1,11,12 In our case, we identiﬁed B.
hominis by stool culture.
Although asymptomatic carriers account for a large percentage
of patients with B. hominis and their treatment remains a matter
of debate, we administered our treatment based on the following
reasons.1,6,13 In Taiwan, many foreign nationals have migrated for
employment in recent decades. Since the prevalence rate of B. homi-
nis in these people is 14.1% and higher than the native residents
of Taiwan, we should recognize B. hominis infection as a prior-
ity in the differential diagnosis of gastrointestinal symptoms.14 B.
hominis may  be silent in its carriers, producing no noticeable symp-
toms. However, B. hominis can be a harmful opportunistic pathogen
in immunocompromised hosts such as human immunodeﬁciency
virus (HIV)-positive patients or organ-transplant patients who
receive immunosuppressive agents.4 Our patient, who underwent
aortic valve and mitral valve replacements and needed the support
of ECMO and IABP, was  immunocompromised to a certain extent.
Although the powerful life support system, ECMO,  is no longer dif-
ﬁcult to implement in Taiwan, subsequent infection is a serious
problem, which may lead to severe irreversible complications such
as death.5,15 Due to the aforementioned concerns, investigation of
the possibility of infection of B. hominis deserved high priority in
our case, since our patient exhibited no signs of infection except for
presence of B. hominis in the gastrointestinal tract.
Therefore, we treated our patient for B. hominis to prevent
his situation from deteriorating when he exhibited hemodynamic
instability. Past research has shown that such patients can be
effectively treated with a range of antibiotics, including metronida-
zole, trimethoprim-sulfamethoxazole (TMP-SMX), ketoconazole,
pentamidine, iodoquinol, tinidazole, and ornidazole.13,16 The most
common agent is metronidazole, with the standard treatment pro-
tocol being oral administration of 500–750 mg three times daily
for 7–10 days. In our case, we prescribed oral metronidazole
500 mg  three times daily for 13 days. The patient’s general condi-
tion improved without further fever or abdominal discomfort after
administration of metronidazole.
So far as we know, no studies of patients on ECMO support
infected by gastrointestinal pathogens such as B. hominis have
previously been published, nor is there any published research dis-
cussing the importance of using prophylactic oral antibiotics to
treat possible digestive infections. We  suggest that prophylactic
medication should be administered routinely when patients live in
a region with a high prevalence of B. hominis and extracorporeal
life-support is used, though further studies are required to validate
this assertion.
4. Conclusion
This is the ﬁrst published article showing that the opportunis-
tic pathogen, B. hominis, can cause severe infection in patients on
ECMO support, a result that should be kept in mind when patients
come from a place with a high prevalence of B. hominis. Although
B. hominis usually is not harmful and has a self-limited course,
patients with hemodynamic instability should be treated for it to
prevent further complications and mortality.Conﬂict of interest
None declared.
FE
a
d
R
O
T
p
cCASE  REPORT  –  OPEN  ACCESS
C.-H. Chen et al. / International Journal of Surgery Case Reports 5 (2014) 637–639 639
unding
None declared.
thical approval
The authors have obtained the informed consent of the patients
nd/or subjects mentioned in the article. The author for correspon-
ence is in possession of this document.
Author contributions
Towards the organization of this work, Nai-Kuan Chou con-
tributed original conception of the study. Chih-Hsuan Chen made
data acquisition and drafted the manuscript. Hsin-Yun Sun pro-
vided opinions about B. hominis infection and helped Hong-Shiee
Lai in revising the manuscript. Hsiung-Fei Chien performed data
analysis and interpretation. Finally, Nai-Kuan Chou approved of the
ﬁnal version of the manuscript for publication.
Key learning points
• This is the ﬁrst published article showing that the opportunistic pathogen, B. hominis, can cause severe infection in
patients on ECMO support.
• The patients with hemodynamic instability should be treated for it to prevent further complications and mortality.
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